FDA Approved: LEQEMBI — Supplemental Application (Eisai Inc.)

View source ↗

Summary

The FDA approved Eisai’s supplemental application for LEQEMBI (lecanemab). The action updates its approved labeling/indication related to Alzheimer’s disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• LEQEMBI (lecanemab)

Snippet

SUPPL AP for LEQEMBI (LECANEMAB)